The Potential of Candesartan to Retard the Progression of Aortic Stenosis
Information source: Helsinki University
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Aortic Valve Stenosis
Intervention: candesartan (Drug); placebo (Drug)
Phase: Phase 3
Status: Recruiting
Sponsored by: Helsinki University Official(s) and/or principal investigator(s): Markku Kupari, MD, PhD, Principal Investigator, Affiliation: Division of Cardiology, Helsinki University Central Hospital
Overall contact: Markku Kupari, MD, PhD, Phone: 358-9-4717-2441, Email: markku.kupari@hus.fi
Summary
The present study defines a blinded, randomized, placebo-controlled, prospective study, the
aim of which is to determine the influence of effective treatment with Type 1 angiotensin II
(Ang II) receptor (AT-1R) antagonist, using candesartan (target dose 16 mg) on stenotic
aortic valves. The investigators will specifically quantify whether candesartan attenuates
the key pathogenic mechanisms of aortic valve stenosis, namely inflammation, fibrosis,
elastin degradation, calcification, and neovascularization.
Clinical Details
Official title: The Potential of Candesartan to Retard the Progression of Aortic Stenosis Influences of Medical Therapy to the Atheroinflammatory Process in Stenotic Aortic Valves
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: The degree of inflammation in stenotic aortic valves
Secondary outcome: The degree of calcification, lipid accumulation, and fibrosis in stenotic aortic valves
Detailed description:
We will include in the study 120 consecutive patients with clinically significant,
symptomatic aortic stenosis referred to the Helsinki University Central Hospital for
consideration of valve replacement surgery. Patients who can be put on the hospital's normal
waiting list for elective angiography (i. e who do not need urgent surgery) and who give
their informed consent, will be randomized into two groups to start therapy with candesartan
(8 mg/d for 2 weeks, and then 16 mg/d until surgery) or placebo. On average, the overall
duration of the drug intervention will be 3 months, i. e., the average time in our
institution from referral to surgery. In addition, patients (n=50) undergoing aortic valve
replacement surgery due to aortic regurgitation caused by dilation of the aortic root will
be included. This population consists of both patients with early sclerotic, i. e.,
pre-stenotic, changes in their aortic valves (n=30) and of patients without any sclerotic or
stenotic changes in their aortic valves (n=20). The group with sclerotic changes in their
aortic valves (n=30) will be divided into two groups to receive candesartan (8 mg/d 2 wk,
and then 16 mg/d until surgery) (n=15) or placebo (n=15). The removed aortic valves will be
examined utilizing real-time PCR, autoradiography, fluorometry, immunohistochemistry, double
immunofluorescence, confocal microscopy, and enzyme immunoassays. With these techniques,
several markers of inflammation, calcification, fibrosis, and the amount of lipid
accumulation and oxidation of LDL in the valves will be examined.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 120 consecutive patients with clinically significant, symptomatic aortic stenosis
referred to the Helsinki University Central Hospital for consideration of valve
replacement surgery.
Exclusion Criteria:
- Individuals with past myocardial infarction, more than mild mitral valve disease, or
previous cardiac surgery will be excluded.
- Patients with heart failure who need urgent surgery or those with hypotension
(systolic blood pressure below 110 mm Hg) will be excluded.
- Patients already taking ACE inhibitors or AT-1R antagonists will be excluded from the
study population.
- Other exclusion criteria include the following:
- Complicated diabetes
- Primary cardiomyopathy
- Pregnant women, women who are breast feeding, and women of childbearing
potential who are not using chemical or mechanical contraception or have a
positive serum pregnancy test
- History of malignancy (unless a documented disease free period exceeding 5-years
is present) with the exception of basal cell or squamous cell carcinoma of the
skin. Women with a history of cervical dysplasia would be permitted to enter the
study provided they had 3 consecutive clear Papanicolaou (Pap) smears
- Hypothyroidism (TSH 1. 5xULN)
- History of alcohol or drug abuse within the last 5 years (this may affect
compliance)
- Unexplained creatine kinase (CK 3xULN) (To protect patient safety)
- Serum creatinine >176 umol/L (2. 0mg/dL)
- Participation in another investigational drug study less than 4 weeks before
enrolment in the study, or according to subjects local ethics committee
requirements where a larger period is stipulated (to avoid potential
misinterpretation of overlapping adverse events)
Locations and Contacts
Markku Kupari, MD, PhD, Phone: 358-9-4717-2441, Email: markku.kupari@hus.fi
Division of Cardiology, Helsinki University Central Hospital, Helsinki 00029, Finland; Recruiting Markku Kupari, MD, PhD, Phone: 358-9-4717-2441, Email: markku.kupari@hus.fi Satu Helske, MD, PhD, Phone: 358-9-681-411, Email: satu.helske@wri.fi Markku Kupari, MD, PhD, Principal Investigator
Additional Information
Starting date: May 2009
Last updated: May 18, 2009
|